^
Association details:
| Biomarker: | BCL2 mutation |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
Published date:
12/06/2020
Excerpt:
...141 patients were enrolled and treated with daily oral ibrutinib (420 mg or 560 mg) plus intravenous nivolumab...In FL and RT, genes with different mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p = 0.047) and ROS1 (0% vs. 50.0%; p = 0.044), respectively...
DOI:
10.1016/j.tranon.2020.100977
Trial ID:
